You are here: Home > About us > News and events > Lung Cancer Awareness Month: New multilingual AI platform supports patients undergoing lung cancer investigations

Lung Cancer Awareness Month: New multilingual AI platform supports patients undergoing lung cancer investigations

17 November 2026

Patients undergoing diagnosis for possible lung cancer at Chelsea and Westminster Hospital can now access multilingual information, personalised guidance and answers to common questions through a new AI-powered platform launched during Lung Cancer Awareness Month.

Patients undergoing diagnosis for possible lung cancer at Chelsea and Westminster Hospital can now access multilingual information, personalised guidance and answers to common questions through a new AI-powered platform launched during Lung Cancer Awareness Month. 

The Lung Cancer Digital Avatar Project (LCDAP), powered by OcciAI, has been developed by clinicians at the Trust to help patients better understand the tests, scans and appointments involved in investigating suspected lung cancer. 

After being referred to hospital, patients may face multiple appointments over a short period while coping with uncertainty about a potential cancer diagnosis. Information is often shared across appointments and telephone calls, making it difficult to take everything in and remember key details at what can be a stressful time. 

The platform aims to support patients through their diagnostic journey by providing access to trusted information about their investigations. Patients can learn about upcoming procedures, revisit information after appointments, ask questions between consultations and access support in their preferred language. Family members and carers can also use the resource to better support their loved ones. 

The platform features a series of short videos using AI-powered digital avatars representing members of the lung cancer multidisciplinary team. The video content helps explain the tests patients may undergo, why they are needed and what to expect when they arrive for their appointments. Additional resources include written information, animations and an AI-supported question-and-answer function in patients' preferred language, drawing on trusted clinical resources. 

Information is available in English and will initially be rolled out in the 10 most translated languages. The combination of spoken, written and visual information has been designed to support people with different levels of health literacy, helping to reduce language barriers and improve access to information for patients and their families. 

Patient involvement has been central to the development of the platform. Working with the Roy Castle Lung Cancer Foundation, the UK's only charity dedicated to supporting everyone affected by lung cancer, the team gathered feedback from patient advocates and people with lived experience of the disease. Their insights helped shape both the design and content of the resource. 

Feedback from patient advocates led to meaningful changes to the platform, including a warmer and more supportive introduction and additional educational content about molecular testing and mutation-driven lung cancers. 

The project was supported by CW Innovation, the Trust’s joint innovation programme with official Trust charity CW+, which supports staff to develop and scale innovations that improve patient care and experience. The project was funded by MSD. 

Launching during November, which marks Lung Cancer Awareness Month, the platform will be rolled out to patients on the suspected cancer pathway, with the hope that the approach could be adapted for other cancer pathways and healthcare services in the future. 

Clinicians hope the platform will improve patient understanding and confidence, reduce avoidable queries and missed appointments, and allow more clinical time to be focused on patients requiring additional support.